Please login to the form below

Not currently logged in

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

AstraZeneca (AZ) has been force to halt the development of obesity drug AZD2820 with US biotech Palatin after a serious adverse event occurred during an early stage trial.

The phase I trial was discontinued in June, 2012, after one subject was suspected to have had a significant allergic reaction following his first dose of the drug. He was subsequently treated at the clinical site and has since fully recovered.

AZ was unable to rule out a link to AZD2820 in its investigation into the trial and so decided to abandon the candidate but not its broader collaboration with Palatin.

This follows the investigation's conclusion that the trial problems were unlikely to be related to melanocortin receptor activation as an approach for the treatment of obesity, which is focus of the AZ-Palatin deal.

“The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca,” said Dr Carl Spana, president and CEO of Palatin.

“We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity.”

The decision to drop AZD2820 is still a major blow for Palatin, however, and shares fell 5 per cent as the news emerged.

It also hurts AZ, with the company having already endured a series of trial disappointments that led to the departure of CEO David Brennan in April.

The obesity market is a difficult one to crack, with weight loss having notorious links with adverse events during the past couple of decades.

High profile casualties have included fenfluramine and dexfenfluramine, both of which were pulled in the 1990s after they were linked to heart problems.

This trend was recently bucked when in June Eisai's Belviq (lorcaserin HCl) became the first obesity drug approved in the US in 13 years, and was shortly followed by approval for Vivus' Qsymia (phentermine/topiramate).

10th September 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...